Epidemiological Parameters of SARS-CoV-2 in the UK during the 2023/2024 Winter: A Cohort Study

Christopher E. Overton^{*1,2}, Martyn Fyles², Jonathon Mellor², Robert S. Paton², Alexander M. Phillips^{2,3}, Alex Glaser², Andre Charlett⁴, and Thomas Ward²

¹ Department for Mathematical Sciences, University of Liverpool

² Infectious Disease Modelling Team, All Hazards Intelligence, Data Analytics and Surveillance, UK Health Security Agency

³ Department for Electrical Engineering and Electronics, University of Liverpool

⁴ Statistics, Modelling, and Economics, Analytics & Data Science, Data Analytics and Surveillance, UK Health Security Agency

*Corresponding author: c.overton@liverpool.ac.uk

Abstract

Estimating epidemiological parameters is essential for informing an effective public health response during waves of infectious disease transmission. However, many parameters are challenging to estimate from real-world data, and rely on human challenge studies or mass community testing. During Winter 2023/2024, a community cohort study of SARS-CoV-2 was conducted across households in England and Scotland. From this survey, questionnaire data and follow-up testing protocols provided valuable data into multiple epidemiological parameters: namely, the duration of positivity, test sensitivity, and the incubation period. Here, Bayesian statistical modelling methods are developed and applied to estimate the underlying parameters. The duration of LFD positivity is found to increase with increasing age, with a mean of 8.55 days (95% Crl: 7.65 days, 9.44 days) in the youngest age group compared to 10.27 days (95% Crl: 9.85 days, 10.71 days) in the oldest age group. Similarly, test sensitivity, as a function of time since symptom onset, decays fastest in the youngest age group, reaching a minimum sensitivity of 0.26 (95% Crl: 0.16, 0.37) compared to 0.54 (95% CrI: 0.46, 0.6). Such patterns are expected since younger individuals experience less severe symptoms of COVID-19 and are likely to clear the virus faster. Combining the duration of positivity and test sensitivity, we estimate the probability of returning a positive test. Close to symptom onset date, this probability is approximately 95%. However, this rapidly drops off, dropping below 5% after 11.3 days (95% Crl: 9.7 days, 13 days) for the youngest age group and 16.2 days (95% Crl: 15.4 days, 17.1 days) for the oldest age group. For the incubation period, there is no clear pattern by age. Across all age groups, the mean incubation period is 2.52 days (95% CrI: 2.42 days, 2.62 days). This is shorter than the most recent estimates for Omicron BA.5, which is in line with earlier research that found replacing variants had shorter incubation periods.

Key words

COVID-19; sensitivity; incubation period; positivity; duration

1 1. Introduction

- 2 SARS-CoV-2, the virus that causes COVID-19, continues to cause resurgent global epidemics. The
- 3 emergence of novel variants of SARS-CoV-2 has been driven by mutation from selective pressures
- 4 and within-host factors. These mutations can lead to viral phenotypic changes that impact
- 5 epidemiological parameters, such as the lower risk of mortality with Omicron relative to Delta [1–5],
- 6 or shorter incubation periods of replacing variants [6–8]. To inform an effective public health
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
 response, understanding how these parameters change is vital for surveillance and policy.

- 8 During the height of the pandemic, mass testing data [9] and contact tracing data [10], alongside
- 9 controlled studies, such as human challenge studies [11], were a valuable source of data on many
- 10 epidemiological parameters, such as the incubation period and duration of positivity. Since April
- 11 2022, these surveillance efforts have been scaled down in the UK, with the Office for National
- 12 Statistics (ONS) COVID-19 Infection Survey (CIS) concluding in March 2023. Similar reductions in
- 13 surveillance data occurred globally, leading to uncertainty in these parameters. During Winter 23/24,
- 14 the UK Health Security Agency (UKHSA) and ONS conducted a new community prevalence study to
- 15 determine SARS-CoV-2 dynamics in England and Scotland. In this study, a randomly sampled cohort
- 16 were tested using Lateral Flow Device (LFD) tests independently of symptom status to evaluate the
- trends of SARS-CoV-2 in the community [12]. However, as part of the study design, additional data
 were collected that provides valuable insights into multiple epidemiological parameters.
- 19 In this paper, data from this survey are used to estimate the duration of LFD positivity, LFD test
- 20 sensitivity, and the current incubation period (the time from becoming infected to developing
- 21 symptoms) of SARS-CoV-2. The most recent estimates of these parameters are limited to the pre-
- Alpha [13], Omicron BA.1 and BA.2 [14], and Omicron BA.5 [8,15] periods, respectively, reducing
- 23 their utility in current public health policy. These parameters are essential in modelling/designing
- 24 different interventions or public health messaging, as well as important parts of infectious disease
- surveillance tools. By providing estimates for these parameters during Winter 23/24, we gain insight
- 26 into the current state of the virus.

27 2. Data

- 28 The UKHSA Winter Coronavirus Infection Survey (WCIS) builds on the success of the ONS CIS survey,
- and uses a subset of the same sample population. Around 150,000 individuals were invited to take
- 30 part in the study, which ran from 13/11/2023 to 27/03/2024. The study design is described in the
- 31 Supplementary Material.
- 32 Upon recruitment to the study, participants were provided with 14 SARS-CoV-2 LFD tests and were
- 33 asked to complete a test every four weeks. Participants then had a 10-day window within which to
- 34 complete those tests. Upon a participant testing positive, they were asked to complete a short
- 35 questionnaire and to complete a follow-up testing protocol by continuing to test every other day
- 36 until two consecutive negative results are observed. This repeat testing protocol, a modification
- 37 from the design of the original ONS CIS, provides key data for estimating sensitivity and the duration
- 38 of positivity.
- A study participant is defined as an individual who returned at least one test result. There were
- 40 123,243 participants, of which 6,395 returned at least one positive test result. A total of 426,667
- 41 tests were performed as part of the main survey, of which 6,466 were positive. This averages 3.46
- 42 tests returned per participant that returned at least one test. This analysis is restricted to
- 43 participants who returned at least one positive test result.
- 44 Unlike the original ONS CIS, participants were not compensated for their participation in the study.
- 45 In addition, because of the re-use of the previous ONS CIS cohort, older individuals were over-
- 46 represented in the sample. A demographic breakdown of the overall study participants is provided in
- 47 the Supplementary Table 1. An age breakdown of study participants used in each model is provided
- 48 in Table 1. Data inclusion criteria for each model are described in the corresponding methods
- 49 sections.

50

Table 1: Age breakdown of the participants included in each model.

Age group	Duration of Positivity	uration of Sensitivity	
	(N=4,567)	(N=3,584)	(N=1405)
3 to 17 years	102 (2.2%)	122 (3.4%)	3 (0.2%)
18 to 34 years	158 (3.5%)	78 (2.2%)	59 (4.2%)
35 to 44 years	451 (9.9%)	360 (10.0%)	95 (6.8%)
45 to 54 years	801 (17.5%)	630 (17.6%)	155 (11.0%)
55 to 64 years	1,313 (28.7%)	1,027 (28.7%)	414 (29.5%)
65 to 74 years	1,193 (26.1%)	933 (26.0%)	481 (34.2%)
75 years and over	549 (12.0%)	434 (12.1%)	198 (14.1%)

51 3. Methods

52 All methods used in this paper are Bayesian methods, implemented in the Stan [16] programming

language, using CmdStanR [17] interfaced through R [18]. For each model, 4 chains were run

54 generating 1000 samples each, with a warmup period of 1000 samples. Convergence of the models

55 was assessed using the \hat{R} statistic [19], with a convergence threshold of $\hat{R} < 1.01$.

56 <u>3.1. Duration of LFD positivity</u>

57 Understanding the duration an individual tests positive for is essential to understand the progression

of a disease. For example, if isolation policies are based on individuals testing positive, it is important

to know the duration of positivity, to determine whether this overlaps with the duration of

60 infectiousness [20]. The duration of positivity is also vital to understand when calculating the

61 incidence rate of new infections from a prevalence estimate.

62 The follow-up testing protocol provides interval-censored data on when individuals are no longer

testing positive. Determining when an individual would start testing positive is challenging, since it

64 will be left-censored at the date when they return their first positive test. To handle this, we instead

65 calculate the duration of LFD positivity as a function of time since symptom onset date, which is

reported in our data for 79% of individuals with at least one positive test. The symptom onset date is

67 interval censored on the date that participants reported developing symptoms. We note, however,

68 that only 8 positive tests occurred prior to the self-reported symptom onset of a case. This is

69 expected since antigen levels only start to rise very close to symptom onset date [21].

70 For inclusion in the duration of positivity model data, data on an individual's first positive test were

71 linked to data from their follow-up testing. From this, the dates of the first positive test and last

72 positive test were calculated. Data were cleaned by removing individuals with inconsistent testing

dates. Of the 6395 individuals who submitted a positive test in the main survey, 4599 had a

corresponding record in the repeat testing data. 32 records were removed due to inconsistent

testing dates, leaving a final sample size of 4567 individuals. For the 8 individuals with positive tests

76 prior to symptom onset date, we treat these as asymptomatic infections.

We consider two random variables, the time of symptom onset, *S*, and the time of last positive, *L*, where L > S. We are interested in the distribution of times between these two events, which we denote by the random variable $\tau \in \mathbb{R}_+$. Both types of data are considered interval censored:

- 80 $S \in [s_1, s_2]$, where $s_1 =$ "Symptom onset date" and $s_2 =$ 81 "Symptom onset date plus 24 hours"
- 82 $L \in [l_1, l_2]$, where $l_1 =$ "Last positive test date" and $l_2 =$ 83 "First negative test date plus 24 hours".

- 84 The 24 hours are added to each event since we only know the date and not the time of each event,
- so it could happen any time within that 24-hour window. Note that for l_2 , we only consider negative
- 86 tests that occur after the last positive date, assuming that any earlier negatives are false negatives.

87 If the individual did not return any negative tests during their follow up testing, then $l_2 = \infty$, i.e., the

data are right-censored. If the individual does not have a symptom onset date, we treat the data as left-censored by the date of the first positive test, i.e., $s_1 = -\infty$ and $s_2 =$

90 "First positive test date plus 24 hours". Based on these different censoring scenarios, there are

91 four possible combinations that a data point can experience: (i) double-interval censoring, where the

92 end points of each censoring interval are known; (ii) right-censoring, where the first event is interval

93 censored and the second event is right-censored; (iii) left-censoring, where the first event is left-

- 94 censored and the second event is interval censored; and (iv) left and right censoring, where the first
- event is left-censored and the second event is right censored. In each of these scenarios, we have aslightly different likelihood function. By considering distinct likelihood functions we make the model
- 97 computationally feasible.

98 (i) Doubly-interval censored data

99 To model the duration of positivity, we wish to evaluate the following likelihood function

100
$$\mathbb{P}(l_1 < L < l_2 \cap s_1 < S < s_2) = \int_{s_1}^{s_2} \int_{l_1}^{l_2} f_{L,S}(L = l, S = s) dl ds$$

101
$$= \int_{s_1} \int_{l_1} f_{L,S}(L = l^* | S = s^*) f_S(S = s) dl ds$$

102
$$= \int_{s_1}^{s_2} \int_{l_1}^{l_2} f_P(l-s) f_S(S=s) dl ds, \qquad (1)$$

where
$$f_P$$
 is the probability density function of the duration of positivity distribution. Implementing
the likelihood in this form requires numerically evaluating a double integral, which is

105 computationally expensive. Instead, we opt to use a latent variable approach [22–24], where we 106 assume uniform prior distributions across the interval censored windows, i.e., $f_L(L = l) = \frac{1}{l_2 - l_1}$ and 107 $f_S(S = s) = \frac{1}{s_2 - s_1}$, and sample the values of *S* and *L* from within their intervals by implementing:

- 108 $l^* \sim \text{Uniform}(l_1, l_2).$

109
$$s^* \sim \text{Uniform}(s_1, s_2),$$

110 Likelihood =
$$f_P(l^* - s^*)$$
.

Here, since l^* follows a uniform distribution, adding the probability density function of l^* to the integrand in Equation (1) (which is implicitly done by the latent variable method) will not affect the results since it only adds a constant to the integrand.

114 (ii) Right-censored data

115 If our data are right-censored, the likelihood function is

116
$$\mathbb{P}(l_1 < L < \infty \cap s_1 < S < s_2) = \int_{s_1}^{s_2} \int_{l_1}^{\infty} f_P(l-s) f_S(S=s) dl ds$$

117
$$= \int_{s_1}^{s_2} f_S(S=s)(1-F_P(l_1-s)) \, \mathrm{d}s.$$

118 We again use a latent variable approach, but only a single latent variable is needed:

119
$$s^* \sim \text{Uniform}(s_1, s_2),$$

120

Likelihood = $1 - F_P(l_1 - s^*)$.

121 (iii) Left-censored data

Following similar logic to the right-censored model, if our data are left-censored, the likelihoodfunction is

124
$$\mathbb{P}(l_1 < L < l_2 \cap -\infty < S < s_2) = \int_{-\infty}^{s_2} \int_{l_1}^{l_2} f_P(l-s) f_S(S=s) dl ds \propto \int_{l_1}^{l_2} 1 - F_P(l-s_2) dl,$$

where an improper flat prior is implicitly used to model $f_S(S = s) = c \ \forall s \in [-\infty, s_2]$. Using latent variables, we model this as

127
$$l^* \sim \text{Uniform}(l_1, l_2),$$

128 Likelihood =
$$1 - F_P(l^* - s_2)$$

129 (iv) Left and right censored data

130 If the data are both left and right censored, we have

131
$$\mathbb{P}(l_1 < L < \infty \cap -\infty < S < s_2) = \int_{-\infty}^{s_2} \int_{l_1}^{\infty} f_P(l-s) f_S(S=s) dl ds \propto \int_{l_1}^{\infty} 1 - F_P(l-s_2) dl,$$

132 where an improper flat prior is implicitly used to model $f_S(S = s) = c \forall s \in [-\infty, s_2]$. To solve this

133 exactly would require numerically evaluating the integral or a latent variable approach with a

uniform latent variable bounded between l_1 to ∞ . To avoid any issues with using such an improper

prior, we can instead rewrite the model in terms of a single random variable

136
$$\int_{-\infty}^{s_2} \int_{l_1}^{\infty} f_P(l-s) dl ds = \int_{l_1-s_2}^{\infty} g(t) f_P(t) dt,$$

137 where g(l - s) is the probability density function of the random variable L - S. We can

138 approximate this by assuming $g(\cdot)$ follows a uniform distribution, which gives

139
$$\mathbb{P}(l_1 < L < \infty \cap -\infty < S < s_2) \approx \int_{l_1 - s_2}^{\infty} f_P(t) dt$$

140 Therefore, the likelihood is given by

141 Likelihood = $1 - F_P(l_1 - s_2)$.

142 Under the assumptions of uniform prior distributions for $f_L(L = l)$ and $f_S(S = s)$, the random

143 variable L - S follows a trapezoidal distribution [22,23]. Here, we approximate a trapezoidal

144 distribution spanning from $(l_1 - s_2, \infty)$ which with an improper uniform prior spanning $(l_1 - s_2, \infty)$. 145 This introduces some bias into the estimated variance [22], but has reduced computational cost and

146 improved numerical stability relative to the latent variable approach.

Our model now consists of a loglikelihood that is significantly easier to evaluate, however there are many latent variables present in the model. As a result, while it is now possible to fit the model in a reasonable timeframe it cannot be considered fast. Many of these observations in the loglikelihood

will have identical values of s_1 , s_2 , l_1 , l_2 . We now take advantage of this fact to develop an

approximate model that vastly reduces the number of latent variables, and consequently provides asignificant improvement to the model fitting speed.

153 In our loglikelihood we have terms of the form

154
$$L = \dots + \sum_{i \in G} \log(f_P(l_i^* - s_i^*)) + \sum_{i \in G} \log(f_L(l_i^*)) + \sum_{i \in G} \log(f_S(s_i^*)) + \dots$$

155 where *G* is a group of observations with identical values of s_1, s_2, l_1, l_2 .

- As an approximation, we will introduce random variables $\overline{S_G}$ and $\overline{L_G}$, representing the means of the
- latent variables s_i^* and l_i^* in group G. We will then approximate the loglikelihood as

158
$$L \approx \dots + \sum_{i \in G} \log \left(f_P(\overline{l_G} - \overline{s_G}) \right) + \sum_{i \in G} \log \left(f_{\overline{L_G}}(\overline{l_G}) \right) + \sum_{i \in G} \log \left(f_{\overline{s_G}}(\overline{s_G}) \right) + \dots$$
159
$$= \dots + n \log \left(f_P(\overline{l_G} - \overline{s_G}) \right) + n \log \left(f_{\overline{L_G}}(\overline{l_G}) \right) + n \log \left(f_{\overline{s_G}}(\overline{s_G}) \right) + \dots$$
(2)

160 where *n* is the number of observations in group *G*. Since the latent variables s_i^* and l_i^* have standard

uniform prior distributions, the sample mean of our latent variables, $\overline{L_G}$ and $\overline{S_G}$, are given by

162 Bates(n) distributions. Since the computational complexity of the Bates likelihood function

163 increases with n, to improve numerical efficiency we will approximate the Bates(n) distributions

164 using Beta distributions. For the Bates(n), we have

165
$$\mathbb{E}[\overline{S_G}] = \frac{1}{2}$$

166
$$\operatorname{War}[\overline{S_{G}}] = \frac{1}{12n}$$

To approximate this, we construct a Beta distribution with the same mean and variance. For theBeta distribution, we have

169

$$\mathbb{E}[\overline{S_G}] = \frac{\alpha}{\alpha + \beta},$$

$$\mathbb{V}\operatorname{ar}[\overline{S_G}] = \frac{\alpha\beta}{(\alpha + \beta)^2(\alpha + \beta + 1)}.$$

171 Equating the means gives

172
$$\frac{\alpha}{\alpha+\beta} = \frac{1}{2} \Rightarrow \alpha = \beta$$

173 Equating the variances gives

174
$$\frac{\alpha\beta}{(\alpha+\beta)^2(\alpha+\beta+1)} = \frac{1}{12n} \Longrightarrow \frac{(2\alpha)^2(2\alpha+1)}{\alpha^2} = 12n \Longrightarrow 8\alpha + 4 = 12n.$$

Therefore, we need $\alpha = \beta = \frac{3n-1}{2}$. An alternative approximation would be to use a normal 175 176 distribution, which is accurate for large n due to the central limit theorem. For n between 1 and 12, 177 we compare the Beta and Normal approximation in Supplementary Figure 1. In general, both approximations perform well, but the Beta distribution works better for small values of n, in 178 particular n = 1 where it exactly yields the Uniform(0,1) distribution, as desired. Therefore, we opt 179 to use the Beta approximation throughout. In our preliminary analysis, using the grouped 180 approximation (Equation (2)) was found to lead to indistinguishable results with a substantial 181 182 reduction in computational time.

- 183 Regardless of the censoring scenarios, the likelihood of the model depends on the distribution of the 184 positivity duration, either through the probability density function $f_P(\cdot)$ or cumulative distribution
- function $F_{P}(\cdot)$. The duration of positivity is assumed to follow a right-skewed distribution with a non-

186 zero mode, since positivity cannot end instantaneously. Since viral load distributions vary with age

- 187 [25–27], we assume this distribution can vary with age group. To model this distribution, we assume
- a lognormal distribution, parameterised by the log-mean, $\theta_{1,i}$, and log-standard-deviation, $\theta_{2,i}$,
- 189 parameters, which represent the mean and standard deviation of the logarithm of the distribution,
- 190 for age group *i*. The log-mean parameter is assumed to vary with age, following a hierarchical
- 191 structure, and we assume the log-standard-deviation parameter is fixed for all age groups, i.e. $\theta_{2,i} =$
- 192 θ_2 for all *i*. We model the parameters and latent variables using the following priors,
- 193 $\theta_{1,i} = \theta_1 + \beta_i \sigma_1,$
- 194 $\theta_1 \sim N(0.5, 2.5^2),$
- 195 $\theta_2 \sim \text{InverseGamma}(10,2),$
- 196 $\beta_i \sim N(0,1),$
- 197 $\sigma_1 \sim Exp(5),$

198
$$\overline{l_G} \sim \text{Beta}\left(\frac{3n_G-1}{2}, \frac{3n_G-1}{2}\right),$$

199
$$\overline{s_G} \sim \text{Beta}\left(\frac{3n_G - 1}{2}, \frac{3n_G - 1}{2}\right)$$

200

201 This hierarchical structure assumes that the log-mean parameter for each age group is centred 202 around an average value, with perturbations specific to each age group. These perturbations are 203 assumed to follow a normal distribution with mean of zero and variance of one. The sigma 204 parameter controls the magnitude of the perturbations, i.e. larger values of σ_1 allow individual age groups to have larger deviations from the population average. Therefore, where an individual age 205 206 group has sparse data, the model will revert to the average value, and sufficient data is needed to 207 justify large deviations from the average value. These age effects are additive on the log-mean 208 parameter, which is roughly equivalent to a multiplicative effect on the linear scale (the effect is 209 multiplicative on the median of the modelled distribution). For example, the influence of age on the median, relative to the population average, is a proportional change to the median duration of 210 positivity. For the latent variable priors ($\overline{l_G}$ and $\overline{s_G}$), n_G is the number of observations in group G. 211

212 <u>3.2. LFD test sensitivity</u>

LFD tests are a powerful diagnostic tool due to a very short delay from testing to results. However,

214 this comes at a compromise of reduced sensitivity to small viral loads relative to the gold-standard

PCR tests. Therefore, when using LFD test results to monitor the epidemic, it is essential to quantify the corresponding test sensitivity.

217 Test sensitivity is typically given/interpreted as the probability of obtaining a positive test result,

- given that the tested individual is "currently infected". There is, however, some ambiguity in how
- "currently infected" is defined. In an ideal world, we might define "currently infected" to be
- individuals who have not yet achieved viral clearance or who have a non-zero probability of
- transmission, though in practice it is impossible to determine whether individuals are in either of
- those states. Instead, surrogate definitions of "currently infected" are used. Most commonly, PCR

positivity is used as a surrogate for "currently infected", where an individual is defined as "currently
 infected" if there is a non-zero probability of returning a positive PCR result that is not a false

positive [14,28]. We note that this definition may not correspond to viral clearance, since PCR tests

226 can detect inactive viral fragments a significant length of time after the infection was cleared, nor

does it necessarily correspond to actively infectious cases for the same reason.

228 Since no PCR tests were used in this study, it is impossible to estimate the probability of obtaining a 229 positive LFD result given that an individual is PCR positive. Instead, our definition of "currently 230 infected" must be individuals who have a non-zero probability of returning a positive LFD test result 231 that is not a false positive. In other words, our definition of test positivity is the probability of 232 obtaining an LFD positive result, given that an individual's infection could be detected by an LFD test. 233 As a result, if LFD sample positivity is adjusted to obtain the prevalence, the prevalence is defined as "the prevalence of LFD positive individuals". We consider sensitivity as a function of time since 234 235 symptom onset, as a proxy for time since infection. Therefore, this sensitivity tells us the probability of correctly returning a positive test for someone who is still testing positive a specific number of 236 237 days after symptom onset. The period of the highest infectiousness is in the few days after symptom 238 onset [21], which also corresponds to the period of high LFD test sensitivity, suggesting our definition of "currently infected" will capture the highly infectious individuals. We only consider 239 240 sensitivity after symptom onset, since we are treating this as the time of earliest positivity.

241 For inclusion in the test sensitivity model, we filter the repeat testing follow-up to individuals who 242 submitted an initial positive test in the main survey. For each individual, we observe a sequence of test results starting with a positive, e.g. "positive, positive, negative, positive, negative, negative" 243 244 (Figure 1). The first test in this sequence will always be a positive result, as the individual would not 245 be included in the repeat testing data had they not tested positive in the main survey. Therefore, we remove the first positive repeat testing result as it is not a random variable. It is assumed that once 246 247 an individual begins to return consecutive negative tests they are no longer in the positive state, i.e. 248 if the 6th and 7th tests are both negative, then the individual is no longer considered to be positive as 249 of the 6th test. Each testing sequence necessarily ends with a "positive, negative, negative" 250 subsequence, which implies the test prior to the first observation of two consecutive negatives must 251 be a positive test. Therefore, we also remove the last positive test as it is, by definition, a positive test result and cannot be treated as a random variable. Since we are interested in sensitivity 252

253 conditional on still testing positive, all tests after the last positive test are also removed.

254



Figure 1: Schematic representation of the structure of the repeat testing data and model

257 This reduces the number of follow-up tests to 6758 tests. Individuals with unknown symptom onset

- date are removed, and individuals with negative time from symptom onset to test or symptom onset
 date 25 days or longer before testing date are also removed. This further reduces the number of
- 260 positive tests to 6586, which forms our sample for the test sensitivity model. These tests were
- 261 submitted by 3584 unique participants.

256

275

262 For each test included, we consider this data point as a pair of observations: the number of days 263 from symptom onset, $d \in \mathbb{Z}_+$, drawn from a random variable D, and whether the test result, drawn 264 from a random variable r, is positive (r = 1) or negative (r = 0). Since these data points are all conditional on the individual remaining in a positive state (p = 1), by aggregating the data by values 265 266 of D, we can calculate the test sensitivity as a function of the time from symptom onset. Plotting the observed data (Supplementary Figure 2), we observe a sigmoidal shape to the data, with peak 267 268 sensitivity at D = 0 and a plateau towards the end of the time period. This plateau occurs because 269 we are conditional on individuals still testing positive, and restricting to a maximum of 24 days post 270 symptom onset. If we increased the length of time since symptom onset, it is possible that a further 271 decay in sensitivity would be observed. However, the probability of individuals still testing positive 272 25 days or longer after symptom onset is very low, which would lead to very few data points to 273 inform the model. To capture the observed sigmoidal behaviour, we use a generalised logistic 274 function

$$\mathbb{P}(r=1|p=1, D=d) = L + \frac{U-L}{1+e^{-(s-gd)}},$$

where $L \in [0,1]$, $U \in [0,1]$, $s \in \mathbb{R}$, and $g \in \mathbb{R}_+$ are all parameters to be estimated. L and Urepresent the lower and upper bounds on the sensitivity, respectively. s is a parameter which shifts the curve, representing how soon sensitivity starts to decay. g is a rate parameter, which controls how quickly the sensitivity decays from the upper bound to the lower bound.

To fit the model, we aggregate the data such that for each value of D, we have the number of tests performed, $N_{\text{tests}}(d) \in \mathbb{Z}_+$, and the number of positive tests that occurred, $N_{\text{pos}}(d) \in \mathbb{Z}_{[0,N_{\text{tests}}(d)]}$, ddays after symptom onset, in a population of cases that were still positive d days after symptom onset. We then assume that the observed number of positive tests is sampled from a binomial distribution with number of trials equal to total numbers of tests, and probability of success equal to $\mathbb{P}(r = 1 | p = 1, D = d)$, i.e.

286
$$N_{pos}(d) \sim \text{Binomial}(N_{tests}(d), \mathbb{P}(r=1|p=1, D=d)).$$

Test sensitivity will depend on the viral load of an individual at the time of their test. Since viral load trajectories will vary by age [25–27], test sensitivity is likely to vary with age [1]. To model this, we allow L and g to vary by age, and assume U and s are the same across all age groups, i.e.

290 $L_i \sim \text{Beta}(\mu_L \rho_L, (1 - \mu_L) \rho_L),$

291
$$\mu_L \sim \text{Beta}(4,6),$$

$$\rho_L \sim \text{Exp}(1).$$

294
$$g_i = \frac{1}{\mu_g + \beta_{g,i}\sigma_g},$$

295
$$\beta_{a,i} \sim N(0,1),$$

296
$$\sigma_q \sim \text{Exp}(1)$$

297
$$\mu_{q} \sim N(1.5,1)$$

298
$$s \sim N(4,3)$$

299 A version of the model allowing all 4 parameters to vary by age was developed, but the U and s 300 parameters did not converge. The hierarchical structure for the rate parameter, g_i , acts on the inverse as this aided convergence. This assumes that the inverse of the rate is affected by additive 301 302 perturbations due to the different age groups, where μ_a is the population average inverse rate 303 parameter and $\beta_{q,i}$ are age group specific perturbations with magnitude controlled by σ_q , which 304 leads to non-linear perturbations on the scale of the rate. The hierarchical structure for the lower 305 bound, L_i , assumes that the lower bound for each age group is sampled from a Beta distribution 306 with mean μ_L , and the ρ_L parameter controls the variance of this Beta distribution. This ensures all 307 lower bounds are bounded within the interval (0,1), and allows different age groups to have 308 different lower bounds, but they are pulled towards the mean in the absence of data suggesting 309 otherwise.

310 3.3. Probability of testing positive over time

311 Instead of considering test sensitivity, which is conditional on the individual being in the infected

312 state, we may wish to calculate the probability that an individual returns a positive test result a

313 certain number of days after their infection began. This differs from the test sensitivity definition,

314 since this includes the probability that a negative test is returned because the individual has cleared

the infection. This also differs from the duration of positivity, since that tells us the probability of

316 whether an individual is still actively infected a certain number of days after infection began, rather

317 than the probability that a single test will return a positive result. The probability of returning a

318 positive a certain number of days after an infection is important, since it provides the relationship

- between epidemic incidence and sample positivity which then informs modelling of the epidemic
- 320 trajectory.

321 As with the sensitivity and duration of positivity models, we will consider this as a function of time

322 since symptom onset, rather than time since infection. Therefore, this tells us the probability that a

323 test taken a certain number of days after the symptom onset date will return a true positive test

result, using LFD test positivity as a proxy for infection. Previous studies [13,29–33] have shown that

325 peak LFD sensitivity, which occurs around symptom onset, is comparable to peak PCR sensitivity,

which is considered the gold standard at detecting infection. Therefore, this will accurately describethe probability of detecting an infection using LFD tests.

To calculate the probability of testing positive over time, we will use our results on test sensitivity and duration of positivity. Latting S(d) denote the probability of testing positive d days often

and duration of positivity. Letting S(d) denote the probability of testing positive d days after symptom onset, we have

331
$$S(d) = \mathbb{P}(r = 1 | D = d) = \mathbb{P}(r = 1 \cap p = 1 | D = d),$$

since an individual can only return a true positive test (r = 1) if it is still possible for them to test positive (p = 1). From this, we have

334
$$S(d) = \mathbb{P}(r = 1 \cap p = 1 | D = d) = \frac{\mathbb{P}(r = 1 \cap p = 1 \cap D = d)}{\mathbb{P}(D = d)}$$

$$= \frac{\mathbb{P}(r=1 \cap p=1 \cap D=d)}{\mathbb{P}(p=1 \cap D=d)}$$

$$\mathbb{P}(p = 1 \cap D = d) \qquad \mathbb{P}(D = d)$$

$$= \mathbb{P}(r = 1 | p = 1 \cap D = d) \mathbb{P}(p = 1 | D = d)$$

337
$$= \mathbb{P}(r=1|p=1, D=d)(1-F_P(d)),$$

where $\mathbb{P}(r = 1 | p = 1, D = d)$ is the test sensitivity d days after symptom onset and $1 - F_P(d)$ is the complimentary cumulative distribution function of the duration of positivity.

340 <u>3.4. Incubation period</u>

341 The incubation period describes the time between an individual becoming infected and developing symptoms. Information on time of infection is challenging to obtain. Commonly, contact tracing data 342 343 has been used, where the date of contact between a primary and secondary case can be used as a 344 date of exposure [34], however contact tracing for SARS-CoV-2 is no longer performed in the UK. In 345 the absence of contact tracing data other approaches must be taken. For example, at the beginning 346 of the COVID-19 pandemic, time spent in Wuhan could be used to provide an approximate exposure 347 window [35–37]. In this study, we investigate the potential of asking individuals to identify their exposure date. For some individuals this may be relatively easy, for example if they have contact 348 with a highly symptomatic individual or have infrequent contacts. For individuals with frequent 349 350 potential infectious contacts, the data quality is likely to be lower. To improve the reliability of the 351 reported exposure dates, we limit this analysis to individuals in either 1 or 2 person households. This restriction is made since in larger households it can be challenging to identify the index case, leading 352 353 to incorrectly identified exposure dates. The secondary event, symptom onset date, is easy to 354 measure, and we ask individuals to report when they first developed symptoms.

For inclusion in the data for the incubation period model, we first select individuals with an estimated exposure date, which reduced the sample size to 3949. We then filtered the data to individuals in households of size 1 or 2, reducing the sample size to 2767. Individuals with symptom onset date on the 15th of any month were removed, since this was the default value if the question was not answered, reducing the sample size to 2089. Finally, individuals with inconsistent dates were removed, resulting in a final sample of 1405 individuals.

361 The incubation period describes the time between two epidemiological events, so we are interested in estimating the distribution of the possible time delays, since not all individuals will have the same 362 363 value. In our data, the two events are time of exposure and time of symptom onset. Since not all 364 infected individuals in the study will go on to develop symptoms, we only include an individual in our 365 sample if they have developed symptoms. This introduces right truncation, whereby individuals with 366 an exposure date within the study period but symptom onset date in the future were removed from 367 our sample. This causes the observed time delay distribution to be biased towards shorter time delays. In this study, we are at the end of an epidemic wave, so the impact of the right-truncation 368 369 will be minimal. In addition to the right truncation, our data are interval censored, since we only 370 have an interval during which each event occurred, rather than the precise time. For both events, 371 this interval censoring corresponded to a 24-hour window representing the day on which the event 372 occurred. To correct for the interval censoring and right truncation, we use the Interval-censoring 373 and right-truncation corrected approach (ICRTC) from [38]. Other potential approaches are 374 described in [23], where this approach has been found to be the most accurate.

We consider two random variables, the time of exposure, *E*, and time of symptom onset, *S*, such

that E < S. Our data takes the form of two intervals: the exposure window, $E \in [e_1, e_2]$; and the symptom onset window, $S \in [s_1, s_2]$, which each have a length of one day. The incubation period

378 can be a described by a random variable X which we assume follows a positive-valued right-skewed

distribution. We consider gamma, Weibull, and lognormal distributions, and assess goodness of fit
 through Pareto Smoothed Importance Sampling Leave-One-Out (PSIS-LOO) cross validation [39]. For

each of these distributions, X is parameterised by two parameters, which we denote θ_1 and θ_2 . To

estimate these parameters, we consider the following interval-censoring and right-truncation

383 corrected likelihood function

384
$$e^* \sim \text{Uniform}(e_1, e_2),$$

385 $s^* \sim \text{Uniform}(s_1, s_2),$

386
$$L = \frac{f_X(s^* - e^*)}{F_X(T - e^*)}$$

where f_X and F_X are the probability density function and cumulative distribution function, respectively, of the incubation period.

In addition to the right-truncation and interval-censoring corrections, in the data there is a second mode at zero, suggesting many respondents may have accidentally entered their symptom onset date as their exposure date. Therefore, we remove such individuals from the study. To account for this in the model, we additionally condition on the incubation period being larger than 1 day, which changes the likelihood function to

394
$$e^* \sim \text{Uniform}(e_1, e_2),$$

395
$$s^* \sim \text{Uniform}(s_1, s_2),$$

396
$$L = \frac{f_X(s^* - e^*)}{F_X(T - e^*) - F_X(1)}$$

397 For each distribution, we parameterise the model such that θ_1 represents the log of the mean. θ_2

then represents the log of the standard deviation for the gamma and lognormal distributions, andthe log of the shape parameter for the Weibull distribution.

400 Incubation periods potentially vary by age since the severity of symptoms is highly sensitive to age. 401 To capture this, we consider a hierarchical version of the model, whereby θ_1 and θ_2 are age-specific 402 parameters. We model this as

- 403 $\log(\theta_{1,i}) = \log(\theta_{1,i})$
- 403 $\log(\theta_{1,i}) = \log(\theta_1) + \beta_i \sigma_1,$
- 404 $\log(\theta_{2,i}) = \log(\theta_2) + \alpha_i \sigma_2,$
- 405 $\log(\theta_1) \sim \mathcal{N}(1,2),$
- 406 $\log(\theta_2) \sim \mathcal{N}(1.6,1),$

407
$$\beta_i \sim \mathcal{N}(0,1)$$

- 408 $\alpha_i \sim \mathcal{N}(0,1),$
- $409 \sigma_1 \sim Exp(1),$
- 410 $\sigma_2 \sim \text{Exp}(1).$

411 This assumes a similar hierarchical structure to the other models. The hierarchical assumptions are

412 made on the logarithmic scale for the θ_1 (mean) and θ_2 parameters, which means that the influence

413 of age is multiplicative on the scale of the model parameters. For example, the influence of age on

the mean, relative to the population average, is a proportional change to the mean incubationperiod.

416 **4. Results**

417 <u>4.1. Duration of positivity</u>

418 For all age groups, the duration of positivity has very low early density (Figure 2) because very few individuals are expected to stop testing positive in fewer than 2 days. This is consistent with the raw 419 420 data, where only 0.7% of doubly-interval censored data points had lower bounds on the duration of 421 positivity less than 2 days. Looking across age groups, there was significant variation in the duration of positivity, though with high uncertainty in the youngest age groups (Figure 2, Table 2). The 422 423 youngest age group, 3 to 17 years, has the shortest mean duration of positivity, estimated at 8.55 424 days (95% Credible Interval (CrI): 7.65 days, 9.44 days), and as age increases there is an increasing 425 trend in the mean (with high uncertainty in some age groups), with the maximum mean duration of 426 positivity in the oldest age group, 75 years and over, with an estimate of 10.27 days (95% Crl: 9.85 427 days, 10.71 days). In addition to the mean increasing with age, the upper percentiles of the duration 428 of positivity also increases (Figure 3). For the 3 to 17 years age group, after 15.25 days (95% Crl: 429 13.63 days, 16.89 days), 95% of cases are no longer LFD positive. For the 75 years and over age 430 group, this increases to 18.31 days (95% Crl: 17.51 days, 19.19 days).

431 No data are shown for goodness of fit comparisons due to the censored nature of the data, with

each data point representing an interval of potential observations rather than a single observation,

433 so empirical PDFs/CDFs cannot be calculated.



Duration of positivity probability density function





Duration of positivity survival function

437

Figure 3: Probability that a case is still testing LFD positive. The black line shows the median of the posterior distribution,
 and the grey shaded region is the 95% credible interval.

Table 2: Mean, median, and 95th percentile of the duration of positivity distribution. The given estimates are medians of the
 posterior distribution, and the numbers in brackets are 95% credible intervals.

Age Group	Mean duration of positivity (days)	Median duration of positivity (days)	Duration of positivity 95 th percentile (days)
3 to 17 years	8.55 (95% Crl: 7.65, 9.44)	7.89 (95% Crl: 7.07, 8.71)	15.25 (95% Crl: 13.63, 16.89)
18 to 34 years	8.82 (95% Crl: 8.16, 9.45)	8.14 (95% Crl: 7.54, 8.73)	15.74 (95% Crl: 14.53, 16.92)
35 to 44 years	9.24 (95% Crl: 8.82, 9.68)	8.52 (95% Crl: 8.14, 8.93)	16.47 (95% Crl: 15.67, 17.32)
45 to 54 years	8.93 (95% Crl: 8.60, 9.25)	8.24 (95% Crl: 7.94, 8.53)	15.92 (95% Crl: 15.29, 16.58)
55 to 64 years	9.43 (95% Crl: 9.18, 9.69)	8.7 (95% Crl: 8.48, 8.94)	16.81 (95% Crl: 16.28, 17.40)
65 to 74 years	9.66 (95% Crl: 9.40, 9.94)	8.92 (95% Crl: 8.68, 9.17)	17.24 (95% Crl: 16.68, 17.83)
75 years and over	10.27 (95% Crl: 9.85, 10.71)	9.47 (95% Crl: 9.09, 9.88)	18.31 (95% Crl: 17.51, 19.19)

442

443 <u>4.2. Sensitivity</u>

- 444 Sensitivity is found to vary substantially with age (Figure 4, Table 3), with the minimum sensitivity
- 445 increasing with increasing age. In the youngest age group, the minimum sensitivity is very low,
- 446 plateauing at 0.26 (95% CrI: 0.16, 0.37). In the oldest age group, this increases to 0.54 (95% CrI: 0.46,
- 447 0.60). Peak sensitivity was assumed to be equal across all age groups, with a peak of 0.95 (95% CrI:
- 448 0.92, 0.98) at time of symptom onset. The rate at which sensitivity decays varied across age groups,
- 449 with a pattern of decreasing decay rate with age. That is, not only does the youngest age group have
- 450 the lowest lower bound, but it also reaches the minimum sensitivity the fastest.



451

452 Figure 4: Test sensitivity given a case is still testing positive. The black line shows the median of the posterior distribution,
453 and the grey shaded region is the 95% credible interval. The blue points are the raw data, and the blue shaded region
454 indicates beta distributed 95% confidence intervals around the raw data.

455 **Table 3:** Estimated parameters of the sensitivity model. The given estimates are medians of the posterior distribution, and 456 the numbers in brackets are 95% credible intervals.

Age Group	Decay Rate	Lower bound	Upper bound	Shift
3 to 17 years	1.05 (95% Crl: 0.79, 1.44)	0.26 (95% Crl: 0.16, 0.37)	0.95 (95% Crl: 0.92, 0.98)	4.46 (95% Crl: 3.51, 5.66)
18 to 34 years	0.82 (95% Crl: 0.60, 1.12)	0.42 (95% Crl: 0.30, 0.53)	0.95 (95% Crl: 0.92, 0.98)	4.46 (95% Crl: 3.51, 5.66)
35 to 44 years	0.73 (95% Crl: 0.57, 0.94)	0.40 (95% CrI: 0.33, 0.47)	0.95 (95% Crl: 0.92, 0.98)	4.46 (95% CrI: 3.51, 5.66)
45 to 54 years	0.74 (95% Crl: 0.58, 0.96)	0.34 (95% CrI: 0.27, 0.40)	0.95 (95% Crl: 0.92, 0.98)	4.46 (95% CrI: 3.51, 5.66)
55 to 64 years	0.78 (95% Crl: 0.61, 1.00)	0.45 (95% CrI: 0.40, 0.49)	0.95 (95% Crl: 0.92, 0.98)	4.46 (95% CrI: 3.51, 5.66)
65 to 74 years	0.82 (95% Crl: 0.64, 1.04)	0.51 (95% Crl: 0.46, 0.55)	0.95 (95% Crl: 0.92, 0.98)	4.46 (95% Crl: 3.51, 5.66)
75 years and over	0.67 (95% Crl: 0.52, 0.87)	0.54 (95% CrI: 0.46, 0.60)	0.95 (95% CrI: 0.92, 0.98)	4.46 (95% CrI: 3.51, 5.66)

457

458 <u>4.3. Probability of testing positive</u>

- 459 In the probability of testing positive, we observe a large increasing effect of age (Figure 5), since this
- 460 combines the age signals observed in both the test sensitivity and duration of positivity parameters.
- 461 The probability of testing positive rapidly drops off, as time from symptom onset increases, in the
- 462 youngest age groups, with a considerably slower decline for the oldest age group.
- 463 At zero days from symptom onset, all age groups had 95% (95% Crl: 92%, 98%) probability of testing
- 464 positive (Table 4). For the youngest age group, by 4.8 days (95% CrI: 4.0 days, 5.4 days) from
- 465 symptom onset, this drops to 50% probability of testing positive, dropping below 5% probability
- 466 after 11.3 days (95% Crl: 9.7 days, 13.0 days). For the oldest age group, these thresholds are

467 increased to 7.6 days (95% Crl: 7.3 days, 8.0 days) and 16.2 days (95% Crl: 15.4 days, 17.1 days),
468 respectively.



Probability of testing positive

469

470 *Figure 5:* Probability that an individual returns a positive LFD test result. The black line shows the median of the posterior
 471 distribution, and the grey shaded region is the 95% credible interval.

472 **Table 4:** Threshold values for time from symptom onset above which the probability of a test returning a negative result is

473 above 50% and 95%. The given estimates are medians of the posterior distribution, and the numbers in brackets are 95%
474 credible intervals.

Age Group	Threshold where 50% of tests are negative (days)	Threshold where 95% of tests are negative (days)
3 to 17 years	4.8 (95% CrI: 4.0, 5.4)	11.3 (95% Crl: 9.7, 13.0)
18 to 34 years	6.1 (95% CrI: 5.5, 6.6)	13.2 (95% Crl: 11.9, 14.4)
35 to 44 years	6.5 (95% CrI: 6.2, 6.8)	13.7 (95% Crl: 12.8, 14.5)
45 to 54 years	6.2 (95% CrI: 6.0, 6.4)	12.7 (95% Crl: 12.0, 13.4)
55 to 64 years	6.5 (95% CrI: 6.3, 6.7)	14.3 (95% Crl: 13.8, 14.9)
65 to 74 years	6.7 (95% CrI: 6.4, 6.9)	15.1 (95% Crl: 14.6, 15.7)
75 years and over	7.6 (95% CrI: 7.3, 8.0)	16.2 (95% Crl: 15.4, 17.1)

475

- 476 <u>4.4. Incubation period</u>
- 477 For the incubation period, there was no strong evidence of a difference between the model LOO

478 scores estimated for each distribution (Supplementary Table 2). Weibull had the lowest estimated

479 LOO, so all results are presented using a Weibull distribution, with gamma and lognormal

480 distributions shown in Supplementary Table 3 and Supplementary Figures 3 and 4. There is no clear

- 481 pattern in the incubation period with age (Figure 6, Table 5). Across all ages (Table 5), the mean
- 482 incubation period was 2.52 days (95% CrI: 2.42 days, 2.62 days). The median incubation period was

- 483 slightly shorter, at 2.24 days (95% CrI: 2.14 days, 2.35 days). The 95th percentile of the incubation
- 484 period, by which point we expect 95% of cases to have developed symptoms (Figure 7), was 5.53
- 485 days (95% CrI: 5.31 days, 5.79 days).



Incubation period probability density function

486

487 *Figure 6:* Probability density function of the incubation period. The blue line shows the median of the posterior distribution,
488 and the blue shaded region is the 95% credible interval. The grey histogram shows the raw data (the 3 to 17 years age
489 group data are masked due to low counts).

Table 5: Mean, median and 95th percentile of the incubation period distribution. The given estimates are medians of the
 posterior distribution, and the numbers in brackets are 95% credible intervals.

Age Group	Mean Incubation Period	Median Incubation Period	95 th Percentile of the Incubation Period
All ages	2.52 (95% Crl: 2.42, 2.62)	2.24 (95% CrI: 2.14, 2.35)	5.53 (95% Crl: 5.31, 5.79)
3 to 17 years	2.55 (95% Crl: 2.25, 2.87)	2.34 (95% CrI: 2.04, 2.65)	5.25 (95% Crl: 4.44, 6.12)
18 to 34 years	2.57 (95% Crl: 2.39, 2.86)	2.37 (95% Crl: 2.18, 2.65)	5.31 (95% Crl: 4.83, 5.92)
35 to 44 years	2.54 (95% Crl: 2.35, 2.74)	2.35 (95% Crl: 2.16, 2.56)	5.12 (95% Crl: 4.65, 5.63)
45 to 54 years	2.50 (95% Crl: 2.31, 2.66)	2.32 (95% Crl: 2.11, 2.49)	5.03 (95% Crl: 4.60, 5.46)
55 to 64 years	2.50 (95% Crl: 2.36, 2.61)	2.27 (95% Crl: 2.13, 2.39)	5.26 (95% Crl: 4.96, 5.56)
65 to 74 years	2.62 (95% Crl: 2.50, 2.77)	2.38 (95% Crl: 2.25, 2.53)	5.54 (95% Crl: 5.25, 5.88)
75 years and over	2.53 (95% Crl: 2.36, 2.68)	2.31 (95% Crl: 2.14, 2.47)	5.25 (95% Crl: 4.89, 5.64)



Incubation period cumulative distribution function

493
 494
 Figure 7: Cumulative distribution function of the incubation period. The blue line shows the median of the posterior
 495
 496 distribution, and the blue shaded region is the 95% credible interval. The grey histogram shows the raw data (the 3 to 17
 496 years age group data are masked due to low counts).

497 **5. Discussion**

The Winter Coronavirus Infection Survey in the UK has been a valuable source of information on the SARS-CoV-2 virus. From this survey, data were collected that can support the estimation of parameters that are of value to understanding the ongoing epidemiology of SARS-CoV-2. Given the complexities of the data and real-world biases, statistical modelling methods are needed to maximise the information extracted from the data. We have developed bespoke methods for estimating the duration of positivity and test sensitivity, and deployed the gold standard method for estimating the incubation period [23].

505 The duration of LFD positivity tells us how long after infection an individual remains able to test 506 positive using LFD tests. This is important, as if an individual takes a test too long after infection, it 507 may no longer be possible to test positive, and the infection will go undetected. Therefore, 508 quantifying this distribution is vital when using testing data for infectious disease surveillance. Also, 509 LFD positivity is closely linked to viral load in the individual [14]. The duration of positivity was 510 shortest for the youngest age groups and increased with age. This finding is consistent with data on 511 severity of infection, whereby older individuals are more likely to have severe disease [1,40,41]. 512 Since severity is likely to correspond to higher viral load / slower viral clearance, this suggests that 513 the duration of positivity should be shorter in younger individuals, which has been seen in earlier 514 studies on the duration of viral shedding [25]. The duration of LFD positivity was found to have a 515 mean of 8.55 days (95% Crl: 7.65 days, 9.44 days) days for the youngest age group, which increased with age to 10.27 days (95% CrI: 9.85 days, 10.71 days) in the oldest age group. Compared to 516 517 previous estimates for pre-Alpha variants [13], this has reduced slightly from a median of 11 days 518 (95% confidence interval: 10 days, 12 days) to a median of between 7.89 days (95% Crl: 7.07 days, 519 8.71 days) and 9.47 days (95% CrI: 9.09 days, 9.88 days), depending on the age of the individual. 520 Such a reduction in the duration of positivity could be due to the reduced severity of Omicron sub-521 lineages [2–5] or higher levels of both infection-derived and vaccine-derived immunity. Based on the fitted lognormal distributions, 95% of cases are no longer LFD positive between 13.63 days and
19.19 days after symptom onset, depending on age. In our duration of positivity data, we do not
have data on time of infection. Therefore, duration of positivity is considered as a function of time
from symptom onset. However, in practice some individuals can test positive prior to symptom
onset. In this study, such cases were very rare, suggesting that the probability of testing positive
prior to symptom onset was very low, so this assumption will have a minimal influence on the
results. The low probability of testing positive prior symptom onset is driven by antigen levels only

529 growing shortly before symptom onset [21].

530 Test sensitivity for LFD tests has previously been shown to be lower than the gold-standard PCR tests 531 [13,28,42]. However, despite the reduced sensitivity, due to the greatly improved time-to-result and 532 reduced cost, LFD tests can be a powerful tool in the response to the COVID-19 pandemic [43]. The 533 continued strength of LFDs relies on the test sensitivity remaining at similar levels, or increasing. 534 Early findings for Omicron suggested increased sensitivity (73.0%) relative to Alpha and Delta 535 variants (55.7% and 64.0%, respectively [14]). We estimated LFD test sensitivity as a function of time 536 from symptom onset. Here, the sensitivity is relative to individuals who are still able to test LFD 537 positive. It is possible that some individuals may never have high enough viral loads to test positive by LFD. However, previous estimates suggest that peak LFD sensitivity is comparable to peak PCR 538 539 sensitivity [13]. LFD sensitivity at the peak was 95% (92%, 98%). This quickly decayed in all age 540 groups, though the minimum sensitivity varied by age. In the youngest age group, the minimum 541 sensitivity was lowest, at 0.26 (95% CrI: 0.16, 0.37). In the oldest age group, this increased to 0.54 542 (95% Crl: 0.46, 0.60). Not only did the youngest age groups have the lowest minimum sensitivity, but 543 they also had the fastest rate of decay from maximum to minimum sensitivity. Higher sensitivity in older age groups supports the use of lateral flow tests in clinical settings [44], such as care homes, 544 545 where the majority of patients are elderly. In this analysis, we considered sensitivity as a function of 546 time since symptom onset. Often, sensitivity is reported as a single value [28,45]. From our temporal 547 sensitivity, comparable single values can be generated by weighting the sensitivity distribution by 548 the observed distribution of times from symptom onset for a given cohort. However, such figures 549 are not reported in this analysis since they are highly dependent on the cohort distribution, which 550 are not necessarily consistent between studies. Importantly, LFD test sensitivity in the few days 551 proceeding symptom onset is very high, which overlaps when individuals are most infectious [21] 552 and therefore enables efficient isolation of infectious individuals.

553 Based on the results for test sensitivity and duration of positivity, we calculated the probability of 554 testing positive as a function of time since symptom onset. Whereas sensitivity gives the probability 555 of testing positive given that someone is still infected, this instead gives the probability of testing positive given the number of days ago that the individual was infected. This provides the relationship 556 between infection incidence and test positivity data, which is fundamental to accurate disease 557 558 surveillance. We found that the effect of age was further amplified, with the youngest age group 559 seeing rapid decline in the probability of testing positive, which slowed down as age increased. In 560 the youngest age group, after 4.8 days (95% CrI: 4.0 days, 5.4 days), 50% of tests would no longer 561 test positive, which increased to 7.6 days (95% CrI: 7.3 days, 8.0 days) in the oldest age group. After 562 11.3 days (95% Crl: 9.7 days, 13.0 days), fewer than 5% of tests in the youngest age group return a 563 positive test result. This 5% threshold increases to 16.2 days (95% CrI: 15.4 days, 17.1 days) in the 564 oldest age group. This shows that although LFD tests are reliable for detecting recent infection close 565 to time of infection (using symptom onset as a proxy), their sensitivity rapidly declines so that they 566 do not detect historic infections.

567 The incubation period describes the time between an individual becoming infected and eventually 568 developing symptoms. This is important in the design of isolation strategies, for example, where we 569 need to know how quickly people will develop symptoms after infection. At the start of the SARS-CoV-2 pandemic, incubation period estimates ranged from 4.84 days to 6.4 days [35–37,46]. The 570 mean incubation period in this study was estimated at 2.52 days (95% Crl: 2.42 days, 2.62 days). This 571 572 is shorter than estimates of 2.6 days to 3.8 days for Omicron BA.5 [8,15], which is the most recent variant with estimates in the literature. However, the incubation period was on a decreasing 573 574 trajectory since wild type [6,8], and with countless variants emerging since Omicron BA.4/5, it may 575 be possible for the incubation period to have decreased further. For example, influenza incubation 576 periods are even shorter at 1.71 days [47]. With this incubation period, 95% of individuals have 577 developed symptoms by 5.53 days (95% Crl: 5.31 days, 5.79 days). We found no patterns of changing 578 incubation periods with age, which is consistent with some previous studies [6], though others have 579 identified a weak relationship with age [48]. With the relatively small sample size, such a signal 580 would be hard to detect. The incubation period data relies on individuals estimating their time of 581 infection, which may introduce a bias. For some individuals, this may be accurate, such as those who infrequently leave the house. For individuals in large households, these data are likely to be 582 583 inaccurate due to large number of potential infectors. To mitigate for this, we restricted the analysis 584 to 1 and 2 person households. However, in 2 person households, it is possible that pre-symptomatic 585 transmission can occur, which might bias the estimated exposure dates, leading to an underestimate 586 of the incubation period.

587 6. Conclusion

588 The Winter Coronavirus Infection Study, although designed to improve our understanding of SARS-

- 589 CoV-2 prevalence in the community, has been a valuable source of data on key epidemiological
- 590 parameters. The study design used will be powerful in future community surveillance studies for
- allowing continued estimation of these parameters. Through this study, we have identified large
- changes in the epidemiology. Firstly, the duration of LFD positivity for currently circulating variants
 has reduced relative to pre-Omicron variants. Secondly, LFD test sensitivity remains high, particularly
- shortly after symptom onset, when individuals are likely to be the most infectious. Finally, the
- 595 incubation period has been observed to have declined relative to earlier variants. Understanding the
- 596 current values of these parameters is essential for designing policy and interventions, as well as for
- accurately converting test positivity data to estimates of infection incidence and prevalence, which
- are vital for assessing real-time infection risk in the community.
- 599

600 Ethics Approval

The study received ethical approval from the National Statistician's Data Ethics Advisory Committee.

602

- 603 **Conflict of Interest**
- The authors have declared that no competing interests exist. There was no financial support for thiswork, completed as part of the authors' employment.
- 606607 Acknowledgements
- The authors would like to thank the UKHSA Surveillance and Immunity team and ONS WCIS analysisteam for their contributions.
- 610

611 Data Availability Statement

- 612 Stan code for all models and trace files from the MCMC samplers are available at
- 613 <u>https://github.com/OvertonC/winter_covid_infection_study-parameters.</u>

614 615 UKHSA operates a robust governance process for applying to access protected data that considers:

- 616 the benefits and risks of how the data will be used
 - compliance with policy, regulatory and ethical obligations
 - data minimisation
 - how the confidentiality, integrity, and availability will be maintained
 - retention, archival, and disposal requirements
- best practice for protecting data, including the application of 'privacy by design and
- by default', emerging privacy conserving technologies and contractual controls
- Access to protected data is always strictly controlled using legally binding data sharing contracts.
- 624 UKHSA welcomes data applications from organisations looking to use protected data for public625 health purposes.
- 626 To request an application pack or discuss a request for UKHSA data you would like to submit, contact
- 627 DataAccess@ukhsa.gov.uk.
- 628

617

618

619

620

629 References

- 630 [1] Ward T, Fyles M, Glaser A, Paton RS, Ferguson W, Overton CE. The real-time infection
 631 hospitalisation and fatality risk across the COVID-19 pandemic in England. Nat Commun
 632 2024;15:4633. https://doi.org/10.1038/s41467-024-47199-3.
- Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the
 clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet
 Lond Engl 2022;399:437–46. https://doi.org/10.1016/S0140-6736(22)00017-4.
- 636 [3] Ulloa AC, Buchan SA, Daneman N, Brown KA. Estimates of SARS-CoV-2 Omicron Variant
 637 Severity in Ontario, Canada. JAMA 2022;327:1286–8. https://doi.org/10.1001/jama.2022.2274.
- [4] Hyams C, Challen R, Marlow R, Nguyen J, Begier E, Southern J, et al. Severity of Omicron
 (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: a
 prospective cohort study in Bristol, United Kingdom. Lancet Reg Health Eur 2023;25.
 https://doi.org/10.1016/j.lanepe.2022.100556.
- 642 [5] Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative
 643 analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron
 644 (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. The Lancet
 645 2022;399:1303–12. https://doi.org/10.1016/S0140-6736(22)00462-7.
- [6] Ward T, Glaser A, Overton CE, Carpenter B, Gent N, Seale AC. Replacement dynamics and the
 pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2. Epidemiol Infect
 2023;151:e32. https://doi.org/10.1017/S0950268822001935.
- 649 [7] UK Health Security Agency. COVID-19 Omicron variant: infectious period and asymptomatic650 and symptomatic transmission. GOVUK 2024.
- 651https://www.gov.uk/government/publications/covid-19-omicron-variant-infectious-period-652and-asymptomatic-and-symptomatic-transmission (accessed June 3, 2024).
- [8] Xu X, Wu Y, Kummer AG, Zhao Y, Hu Z, Wang Y, et al. Assessing changes in incubation period,
 serial interval, and generation time of SARS-CoV-2 variants of concern: a systematic review and
 meta-analysis. BMC Med 2023;21:374. https://doi.org/10.1186/s12916-023-03070-8.
- [9] Department of Health and Social Care. Liverpool COVID-19 community testing pilot: interim
 evaluation report summary. GOVUK n.d.
- 658 https://www.gov.uk/government/publications/liverpool-covid-19-community-testing-pilot-659 interim-evaluation-report-summary/liverpool-covid-19-community-testing-pilot-interim-660 evaluation-report-summary (accessed June 3, 2024).
- 661 [10] World Health Organization. Coronavirus disease (COVID-19): Contact tracing n.d.
- 662 https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-663 contact-tracing (accessed June 3, 2024).

- Killingley B, Mann AJ, Kalinova M, Boyers A, Goonawardane N, Zhou J, et al. Safety, tolerability
 and viral kinetics during SARS-CoV-2 human challenge in young adults. Nat Med 2022;28:1031–
 41. https://doi.org/10.1038/s41591-022-01780-9.
 UK Health Security Agency. Winter Coronavirus (COVID-19) Infection Study: quality and
 methodology information. GOVUK n.d. https://www.gov.uk/government/statistics/wintercoronavirus-covid-19-infection-study-estimates-of-epidemiological-characteristics-england-
- and-scotland-2023-to-2024/winter-coronavirus-covid-19-infection-study-quality-and methodology-information (accessed June 3, 2024).
- [13] Davis EL, Hollingsworth TD. Estimating LFT and qPCR test-sensitivity over time since infection
 from a human challenge study 2022. https://doi.org/10.1101/2022.10.18.22280274.
- Eyre DW, Futschik M, Tunkel S, Wei J, Cole-Hamilton J, Saquib R, et al. Performance of antigen
 lateral flow devices in the UK during the alpha, delta, and omicron waves of the SARS-CoV-2
 pandemic: a diagnostic and observational study. Lancet Infect Dis 2023;23:922–32.
 https://doi.org/10.1016/S1473-3099(23)00129-9.
- 678 [15] Ogata T, Tanaka H. SARS-CoV-2 Incubation Period during the Omicron BA.5–Dominant Period
 679 in Japan Volume 29, Number 3–March 2023 Emerging Infectious Diseases journal CDC n.d.
 680 https://doi.org/10.3201/eid2903.221360.
- 681 [16] Stan Development Team. Stan Modeling Language Users Guide and Reference Manual. 2024.
- 682 [17] Gabry J, Češnovar R, Johnson A. cmdstanr: R Interface to "CmdStan." 2023.
- [18] RStudio Team. RStudio: Integrated Development Environment for R. Boston, MA: RStudio,
 PBC.; 2020.
- [19] Vehtari A, Gelman A, Simpson D, Carpenter B, Bürkner P-C. Rank-Normalization, Folding, and
 Localization: An Improved R[^] for Assessing Convergence of MCMC (with Discussion). Bayesian
 Anal 2021;16:667–718. https://doi.org/10.1214/20-BA1221.
- [20] Department of Health and Social Care. [Withdrawn] Self-isolation for those with COVID-19 can
 end after 5 full days following 2 negative LFD tests. GOVUK 2022.
- 690https://www.gov.uk/government/news/self-isolation-for-those-with-covid-19-can-end-after-691five-full-days-following-two-negative-lfd-tests (accessed July 1, 2024).
- 692 [21] UK Health Security Agency. PCR testing for SARS-CoV-2 during the COVID-19 pandemic. GOVUK
 693 n.d. https://www.gov.uk/government/publications/pcr-testing-for-sars-cov-2-during-the 694 covid-19-pandemic (accessed July 1, 2024).
- Reich NG, Lessler J, Cummings DAT, Brookmeyer R. Estimating incubation period distributions
 with coarse data. Stat Med 2009;28:2769–84. https://doi.org/10.1002/sim.3659.
- 697 [23] Park SW, Akhmetzhanov AR, Charniga K, Cori A, Davies NG, Dushoff J, et al. Estimating
 698 epidemiological delay distributions for infectious diseases 2024:2024.01.12.24301247.
 699 https://doi.org/10.1101/2024.01.12.24301247.
- [24] Ward T, Johnsen A. Understanding an evolving pandemic: An analysis of the clinical time delay
 distributions of COVID-19 in the United Kingdom. PLOS ONE 2021;16:e0257978.
 https://doi.org/10.1371/journal.pone.0257978.
- [25] Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in
 patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020:
 retrospective cohort study. BMJ 2020;369:m1443. https://doi.org/10.1136/bmj.m1443.
- 706 [26] Xiao AT, Tong YX, Gao C, Zhu L, Zhang YJ, Zhang S. Dynamic profile of RT-PCR findings from 301
 707 COVID-19 patients in Wuhan, China: A descriptive study. J Clin Virol 2020;127:104346.
 708 https://doi.org/10.1016/j.jcv.2020.104346.
- Yan D, Liu X-Y, Zhu Y, Huang L, Dan B, Zhang G, et al. Factors associated with prolonged viral
 shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients
 with SARS-CoV-2 infection. Eur Respir J 2020;56. https://doi.org/10.1183/13993003.007992020.

713 [28] Mistry DA, Wang JY, Moeser M-E, Starkey T, Lee LYW. A systematic review of the sensitivity and specificity of lateral flow devices in the detection of SARS-CoV-2. BMC Infect Dis 714 715 2021;21:828. https://doi.org/10.1186/s12879-021-06528-3. 716 [29] Quantifying the relationship between SARS-CoV-2 viral load and infectiousness | eLife n.d. 717 https://elifesciences.org/articles/69302 (accessed June 8, 2024). 718 [30] He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and 719 transmissibility of COVID-19. Nat Med 2020;26:672–5. https://doi.org/10.1038/s41591-020-720 0869-5. 721 [31] Hakki S, Zhou J, Jonnerby J, Singanayagam A, Barnett JL, Madon KJ, et al. Onset and window of 722 SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, 723 longitudinal, community cohort study. Lancet Respir Med 2022;10:1061–73. 724 https://doi.org/10.1016/S2213-2600(22)00226-0. 725 [32] Jones TC, Biele G, Mühlemann B, Veith T, Schneider J, Beheim-Schwarzbach J, et al. Estimating 726 infectiousness throughout SARS-CoV-2 infection course. Science 2021;373:eabi5273. 727 https://doi.org/10.1126/science.abi5273. 728 [33] Stankiewicz Karita HC, Dong TQ, Johnston C, Neuzil KM, Paasche-Orlow MK, Kissinger PJ, et al. 729 Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan 730 Strain) in Association With COVID-19 Symptom Onset and Severity. JAMA Netw Open 731 2022;5:e2142796. https://doi.org/10.1001/jamanetworkopen.2021.42796. 732 [34] Manica M, Litvinova M, Bellis AD, Guzzetta G, Mancuso P, Vicentini M, et al. Estimation of the 733 incubation period and generation time of SARS-CoV-2 Alpha and Delta variants from contact 734 tracing data. Epidemiol Infect 2023;151:e5. https://doi.org/10.1017/S0950268822001947. 735 [35] Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) 736 infections among travellers from Wuhan, China, 20–28 January 2020. Eurosurveillance 737 2020;25:2000062. https://doi.org/10.2807/1560-7917.ES.2020.25.5.2000062. 738 [36] Overton CE, Stage HB, Ahmad S, Curran-Sebastian J, Dark P, Das R, et al. Using statistics and 739 mathematical modelling to understand infectious disease outbreaks: COVID-19 as an example. 740 Infect Dis Model 2020;5:409–41. https://doi.org/10.1016/j.idm.2020.06.008. 741 [37] Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung S, et al. Incubation Period 742 and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right 743 Truncation: A Statistical Analysis of Publicly Available Case Data. J Clin Med 2020;9:538. 744 https://doi.org/10.3390/jcm9020538. [38] Ward T, Christie R, Paton RS, Cumming F, Overton CE. Transmission dynamics of monkeypox in 745 746 the United Kingdom: contact tracing study. BMJ 2022;379:e073153. 747 https://doi.org/10.1136/bmj-2022-073153. 748 [39] Vehtari A, Gelman A, Gabry J. Practical Bayesian model evaluation using leave-one-out cross-749 validation and WAIC. Stat Comput 2017;27:1413-32. https://doi.org/10.1007/s11222-016-750 9696-4. 751 [40] Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of 752 coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020;20:669–77. 753 https://doi.org/10.1016/S1473-3099(20)30243-7. 754 [41] Bonanad C, García-Blas S, Tarazona-Santabalbina F, Sanchis J, Bertomeu-González V, Fácila L, et 755 al. The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 756 Subjects. J Am Med Dir Assoc 2020;21:915–8. https://doi.org/10.1016/j.jamda.2020.05.045. [42] Pickering S, Batra R, Merrick B, Snell LB, Nebbia G, Douthwaite S, et al. Comparative 757 758 performance of SARS-CoV-2 lateral flow antigen tests and association with detection of 759 infectious virus in clinical specimens: a single-centre laboratory evaluation study. Lancet 760 Microbe 2021;2:e461–71. https://doi.org/10.1016/S2666-5247(21)00143-9. 761 [43] Department of Health and Social Care. Performance of lateral flow devices during the COVID-762 19 pandemic. GOVUK n.d. https://www.gov.uk/government/publications/lateral-flow-device-

- 763 performance-data/performance-of-lateral-flow-devices-during-the-covid-19-pandemic 764 (accessed July 1, 2024). [44] Department of Health and Social Care. Infection prevention and control (IPC) in adult social 765 766 care: acute respiratory infection (ARI). GOVUK n.d. https://www.gov.uk/government/publications/infection-prevention-and-control-in-adult-767 768 social-care-acute-respiratory-infection/infection-prevention-and-control-ipc-in-adult-socialcare-acute-respiratory-infection-ari (accessed June 3, 2024). 769 [45] Böger B, Fachi MM, Vilhena RO, Cobre AF, Tonin FS, Pontarolo R. Systematic review with meta-770 analysis of the accuracy of diagnostic tests for COVID-19. Am J Infect Control 2021;49:21–9. 771 772 https://doi.org/10.1016/j.ajic.2020.07.011. [46] Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of 773 774 Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and 775 Application. Ann Intern Med 2020;172:577–82. https://doi.org/10.7326/M20-0504. 776 [47] Boëlle P-Y, Ansart S, Cori A, Valleron A-J. Transmission parameters of the A/H1N1 (2009) 777 influenza virus pandemic: a review. Influenza Other Respir Viruses 2011;5:306–16. 778 https://doi.org/10.1111/j.1750-2659.2011.00234.x. 779 [48] Galmiche S, Cortier T, Charmet T, Schaeffer L, Chény O, Platen C von, et al. SARS-CoV-2 780 incubation period across variants of concern, individual factors, and circumstances of infection 781 in France: a case series analysis from the ComCor study. Lancet Microbe 2023;4:e409–17.
- 782 https://doi.org/10.1016/S2666-5247(23)00005-8.
- 783